Published in Hepatitis Weekly, April 3rd, 2000
The project will assess the potential of Biosyntech's BST-GEL as a sustained release system for Viragen's Omniferon, a natural, multi-subtype alpha interferon currently in Phase II clinical trials in Europe for hepatitis C.
Patients treated with interferon for hepatitis C typically receive three injections per week for approximately one year. Biosyntech's sustained release delivery system should potentially reduce the number of injections, reduce the costs, and maximize the compliance and potential...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.